ArticleFrontiers in molecular biosciences2021
Using CRISPRa and CRISPRi Technologies to Study the Biological Functions of ITGB5, TIMP1, and TMEM176B in Prostate Cancer Cells.
Article in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- CRISPRa Lipid Nanocomplex-Mediated Mt3 Targeting Enhances Astrocytic Endocytosis of Amyloid-β in an Alzheimer's Disease Mouse Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- TMEM176B inhibits ovarian cancer progression by regulating EMT via the Wnt/β-catenin signaling pathway.Journal of translational medicine · 2025Article
- Integrating Radiosensitivity Index and Radiation Resistance Related Index Improves Prostate Cancer Outcome Prediction.Advances in radiation oncology · 2025Article
- Decoding Alzheimer's Disease With Depression: Molecular Insights and Therapeutic Target.Journal of cellular and molecular medicine · 2025Article
- Differential gene expression patterns in Niemann-Pick Type C and Tay-Sachs diseases: Implications for neurodegenerative mechanisms.PloS one · 2025Article
- Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signaling.Cell communication and signaling : CCS · 2024Review
- TMEM176B Promotes EMT via FGFR/JNK Signalling in Development and Tumourigenesis of Lung Adenocarcinoma.Cancers · 2024Article
- Identification of circRNA-miRNA-mRNA Network Regulated by Hsp90 in Human Melanoma A375 Cells.Combinatorial chemistry & high throughput screening · 2024Article
- Development and validation of focal adhesion-related genes signature in gastric cancer.Frontiers in genetics · 2023Article
- The prognostic and immune infiltration role of ITGB superfamily members in non-small cell lung cancer.American journal of translational research · 2022Article
- Identification of Prognostic Biomarkers of Glioblastoma Based on Multidatabase Integration and Its Correlation with Immune-Infiltration Cells.Journal of oncology · 2022Article
- TMEM176B Regulates AKT/mTOR Signaling and Tumor Growth in Triple-Negative Breast Cancer.Cells · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although ITGB5, TIMP1, and TMEM176B are abnormally expressed in several cancers, their molecular biological mechanisms in prostate cancer cells are still to be investigated. The gene regulation technogies based on CRISPR transcription factors could be used to investigate the biological functions of genes in cancer. In this study, we used CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) technologies to regulate the transcription of ITGB5, TIMP1, and TMEM176B in prostate cancer cells. Through a series of cellualr experiments, we found that inhibition of ITGB5 or activation of TIMP1 and TMEM176B suppress prostate cancer. The three genes synergistically affect the proliferation, invasion and migration capabilities of cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.